Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis.
Year: 2022
Type: article
Study design: Case Report
Abstract: Targeted therapy has expanded our current treatment options for various diseases including Langerhans cell histiocytosis. However, side effects associated with targeted therapy should be recognized and addressed. In this study, we report a pediatric bilateral pan-uveitis associated with the use of trametinib for Langerhans cell histiocytosis. A 10-year-old boy with Langerhans cell histiocytosis that was being treated by trametinib presented with mutton-fat keratic precipitates, anterior chamber cells, hyperemic swelling discs, subretinal fluid, and choroidal edema in both eyes. He was diagnosed with pan-uveitis in both eyes. When the trametinib therapy was stopped, the symptoms disappeared after local and systematic corticosteroid treatment. In conclusion, MEK (mitogen-activated protein/extracellular signal-related kinase kinase) inhibitor trametinib treatment alone might be associated with ocular toxicity presenting as Vogt Koyanaki Harada syndrome-like pan-uveitis. Ocular symptoms and signs should be monitored carefully during MEK inhibitor therapy.
Source: PubMed Central
Authors: Yu Du, Yun-Tao Hu
Institutions: Beijing Tsinghua Chang Gung Hospital, Tsinghua University
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4315619159
